Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Tria... by Makoto Hibino, MD, Osamu Hiranuma, MD, Yoshizumi Takemura, MD, PhD, Yuki Katayama, MD, Yusuke Chihara, MD, PhD, Taishi Harada, MD, Kohei Fujita, MD, PhD, Toshiyuki Kita, MD, PhD, Nobuyo Tamiya, MD, PhD, Takeshi Tsuda, MD, Shinsuke Shiotsu, MD, Yukihiro Tamura, MD, PhD, Takashi Aoyama, MD, Yoichi Nakamura, MD, PhD, Masaaki Terashima, MD, PhD, Yoshie Morimoto, MD, PhD, Kazuhiro Nagata, MD, PhD, Kenichi Yoshimura, PhD, Junji Uchino, MD, PhD, Koichi Takayama, MD, PhD

Get full text

A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116... by Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD

Get full text